Cell & Gene Therapies: Current Status and Opportunities

17:15 - 18:00

  • Cell & Gene Therapies history – a “bumpy ride” from bench to commercial products
  • CMC focus – from a lab sample to the stable product production
  • From stable product to a patient – regulatory focus
  • A future of ATMPs

Dr. Magdalena Obarzanek-Fojt, Drug Product Leader within Cell and Gene Technical Development, Novartis